Importantly, using the TGF-β type I receptor kinase inhibitor, LY364947 successfully reversed CHPF-silencing-enhanced cell viability, cell migration, and invasion (Figure 5B,C), suggesting that TGF-β signaling participates in CHPF-regulated malignancy of HCC cells. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.